In October 2012, Ligocyte Pharmaceuticals Inc was acquired by Japanese firm Takeda Pharmaceuticals for $60M in cash. LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. The firm has produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry
